Moleculin Biotech Files 8-K
Ticker: MBRX · Form: 8-K · Filed: Dec 16, 2025 · CIK: 1659617
Sentiment: neutral
Topics: corporate-update, sec-filing
TL;DR
Moleculin Biotech filed an 8-K on Dec 15, 2025, updating its corporate address.
AI Summary
On December 15, 2025, Moleculin Biotech, Inc. filed an 8-K report. The filing indicates the company's principal executive offices are located at 5300 Memorial Drive, Suite 950, Houston, TX 77007. The report was filed as of December 16, 2025, and pertains to events reported on December 15, 2025.
Why It Matters
This 8-K filing serves as an official notification of corporate events, providing transparency to investors regarding the company's operational and administrative updates.
Risk Assessment
Risk Level: low — This filing is a routine administrative update and does not contain information that inherently increases or decreases risk.
Key Players & Entities
- Moleculin Biotech, Inc. (company) — Registrant
- 5300 Memorial Drive, Suite 950, Houston, TX 77007 (location) — Principal executive offices
- December 15, 2025 (date) — Date of earliest event reported
- December 16, 2025 (date) — Filing date
FAQ
What is the primary purpose of this Form 8-K filing?
The primary purpose is to report current information about the company as required by the SEC, specifically noting events that occurred on December 15, 2025.
What is Moleculin Biotech, Inc.'s principal executive office address?
The principal executive offices are located at 5300 Memorial Drive, Suite 950, Houston, TX 77007.
On what date was the earliest event reported in this filing?
The earliest event reported was on December 15, 2025.
When was this Form 8-K filed with the SEC?
This Form 8-K was filed as of December 16, 2025.
What is the company's state of incorporation?
The company is incorporated in Delaware.
Filing Stats: 520 words · 2 min read · ~2 pages · Grade level 10.2 · Accepted 2025-12-16 17:20:58
Key Financial Figures
- $1.00 — mmon stock had closed below the minimum $1.00 per share requirement for continued inc
Filing Documents
- mbrx20251215_8k.htm (8-K) — 22KB
- logosmall.jpg (GRAPHIC) — 3KB
- 0001437749-25-038047.txt ( ) — 159KB
- mbrx-20251215.xsd (EX-101.SCH) — 3KB
- mbrx-20251215_def.xml (EX-101.DEF) — 12KB
- mbrx-20251215_lab.xml (EX-101.LAB) — 15KB
- mbrx-20251215_pre.xml (EX-101.PRE) — 12KB
- mbrx20251215_8k_htm.xml (XML) — 3KB
01 Other Events
Item 8.01 Other Events. As previously reported, on June 27, 2025, Moleculin Biotech, Inc. (the "Company") received a deficiency letter from the Listing Qualifications Department (the "Staff") of the Nasdaq Stock Market ("Nasdaq") notifying the Company that for the last 30 consecutive business days the bid price for the Company's common stock had closed below the minimum $1.00 per share requirement for continued inclusion on the Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the "Bid Price Rule"). On December 15, 2025, the Company received a letter from the Staff notifying the Company that it had regained compliance with the Bid Price Rule as a result of the closing bid price of the Company's common stock being at $1.00 per share or greater for the 10 consecutive business days from December 1, 2025 through December 12, 2025. Accordingly, the letter indicated the Company is in compliance with the Bid Price Rule and the matter is closed. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. MOLECULIN BIOTECH, INC. Date: December 16, 2025 By: /s/ Jonathan P. Foster Jonathan P. Foster Chief Financial Officer